New publication evidences role of medical cannabis in epilepsy
UK medical hashish specialists have printed a complete evaluate of proof for the prescription of cannabis-based medicines in epilepsy.
With over 280 references to peer-reviewed literature, Medical Cannabis & Epilepsy, printed by Maple Tree Consultants, offers the primary evaluate of practically 100 scientific trials, real-world research, and observational analysis on the position of Hashish-Primarily based Medicinal Merchandise (CBMPs) in epilepsy administration.
Co-written by Professor Mike Barnes, Hannah Deacon and Varinder Kaur, it goals to function an important useful resource for healthcare professionals, sufferers, and regulators looking for a deeper understanding of the usage of CBMPs, notably in sufferers with drug-resistant epilepsy.
Key subjects lined embody an in depth introduction to varieties, causes, and signs of epilepsy; how cannabinoids modulate mind pathways to cut back seizures; the proof surrounding the usage of THC in paediatric epilepsy; and potential interactions between CBMPs and epilepsy drugs.
There’s additionally a powerful concentrate on real-world information and the way patient-reported outcomes are shaping the way forward for epilepsy remedy.
Prof Barnes, co-founder of Maple Tree Consultants and the primary physician to acquire a license to prescribe hashish within the UK, commented: “This publication affords a vital useful resource for clinicians, pulling collectively practically 100 scientific trials, real-world research, and case reviews on the usage of hashish in epilepsy remedy. By compiling this in depth proof, we offer a powerful basis for healthcare professionals to make knowledgeable selections in regards to the efficacy and security of cannabis-based medicinal merchandise.
“As medical hashish continues to reveal its effectiveness in treating epilepsy in lots of sufferers, this information is important for advancing its acceptance and enhancing entry for sufferers who want it most.”
The publication additionally offers in-depth evaluation of the boundaries confronted by sufferers in accessing CBMPs throughout the UK’s regulatory framework, highlighting gaps in NHS entry, the rising reliance on personal clinics, and the monetary pressure households encounter when looking for remedy.
Hannah Deacon, Co-Founding father of Maple Tree Consultants, whose profitable marketing campaign led to son Alfie’s medical doctors receiving the primary schedule one licence to prescribe complete plant hashish on the NHS, mentioned: “For the primary time, this publication pulls collectively the great proof healthcare professionals want to raised help kids and households affected by epilepsy.
“My son Alfie’s life has been fully reworked by medical hashish—from enduring tons of of seizures a month to residing a fuller, happier life. His journey is the rationale I’m so captivated with advocating for kids with refractory epilepsy. I actually hope this publication opens doorways for a lot of extra households, giving clinicians the info they should make knowledgeable selections and enhance entry to this life-changing remedy.”
Co-author, Varinder Kaur, added: “Regardless of hashish being legalised for medicinal use since 2018, sufferers are nonetheless struggling to entry life-saving hashish merchandise by way of the NHS. Many medical doctors refuse to prescribe hashish attributable to restrictive tips and issues concerning the shortage of proof.
“Our publication offers an in-depth dialogue on the preclinical and scientific proof base of hashish and epilepsy to assist educate people from differing backgrounds. Hashish is an efficient remedy for kids with extreme treatment-resistant epilepsy and we hope that this publication might help help wider accessibility of hashish medicines to epilepsy sufferers.”
Medical Hashish & Epilepsy is the second publication in Maple Tree’s Medical Cannabis Evidence Base series and is out there to buy from the website.
